MAPT and Alzheimer disease: Previous studies have found that the synaptic biomarker CSF GAP-43 is associated with tau pathology in Alzheimer’s disease,18,32 and in this study, we also observed that CSF 14-3-3β is associated with CSF GAP-43, highlighting the combination of tau pathology, synaptic dysfunction and 14-3-3β pathological changes of Alzheimer’s disease.